Recombinant Human VIPR2 Fc Chimera Protein, CF

Catalog #: 11003-VR Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
11003-VR-050

Recombinant Human VIPR2 Fc Chimera Protein SDS-PAGE.

1 Image

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VIPR2 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human Growth Hormone-Releasing Factor is immobilized at 2.00 μg/mL, 100 μL/well, Recombinant Human VIPR2 Fc Chimera binds with an ED₅₀of 7.00-42.0 μg/mL.

Source

Human embryonic kidney cell, HEK293-derived human VIPR2 protein

Recombinant Human VIPR2 (Arg26-Val126) Accession # P41587.2	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Accession #

P41587.2

N-terminal Sequence
Analysis

Arg26

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

38 kDa

SDS-PAGE

45-60 kDa, under reducing conditions.

Product Datasheets

11003-VR

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11003-VR

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human VIPR2 Fc Chimera Protein (Catalog # 11003-VR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 45-60 kDa and 90-120 kDa, respectively.

Reconstitution Calculator

Background: VIPR2

Vasoactive intestinal polypeptide receptor 2 (VIPR2 or VPAC2) is a transmembrane receptor that belongs to the B class G protein coupled receptor family of proteins (1). Mature, human VIPR2 consists of an extracellular domain (ECD) with a hormone receptor region followed by seven transmembrane regions and a short cytoplasmic domain. The ECD of human VIPR2 shares 90% amino acid sequence identity with both mouse and rat VIPR2. Human VIPR2 is expressed predominantly in skeletal muscle, and to a lesser extent in the brain, heart, pancreas, and placenta (1). VIPR2 is coupled to a cAMP mediated signal transduction pathway and binds two homologous neuropeptides, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP), with high affinity (1). VIP plays several roles during neural development, including stimulating neurogenesis, promoting survival of neurons, and assisting in neuron repair (1, 2). Additionally, VIP signaling via VIPR2 has been implicated in regulating immune responses (3). VIPR2 gene duplication and altered signaling of VIP has been associated with the pathogenesis of schizophrenia and may also play a role in autism (4-6). VIPR2 activation has been linked to disruption of cortical neuronal maturation in mice (7). Studies suggest that VIPR2 could be a potential target in the development of novel antipsychotic drugs (5).

References

Lutz, E. M. et al. (1999) FEBS Letters. 458:197.
Hill, J. et al. (2007) Curr. Pharm. Des. 13:1079.
Abad, C. and Var Tan, Y. (2016) J Clin Exp Neuroimmunol 1:104.
Vacic, V. et al. (2011) Nature. 471:499.
Levinson, D. et al. (2011) Ameri. J. Psych. 168:302.
Firouzabadi, S. G. et al. (2017) Molec. Neuobio. 54:7019.
Takeuchi, S. et al. (2020) Front. Neurosci. 14:521.

Long Name

Vasoactive Intestinal Peptide Receptor 2

Entrez Gene IDs

7434 (Human); 22355 (Mouse); 29555 (Rat)

Alternate Names

FLJ16511; Helodermin-preferring VIP receptor; PACAP type III receptor; PACAPR3; PACAP-R3; PACAP-R-3; Pituitary adenylate cyclase-activating polypeptide type III receptor; vasoactive intestinal peptide receptor 2; vasoactive intestinal polypeptide receptor 2; VIP R2; VIP2R; VIPR2; VIP-R-2; VPAC2; VPCAP2R